Abeona Therapeutics Inc.

ABEO11 Dec 2024
Healthcare
$5.9
+0.02 (+1.66%)
Lowest Today
$5.87
Highest Today
$6.02
Today’s Open
$5.9
Prev. Close
$5.92
52 Week High
$9.01
52 Week Low
$3.05
To Invest in Abeona Therapeutics Inc.

Abeona Therapeutics Inc.

Healthcare
ABEO11 Dec 2024
+0.02 (+1.66%)
1M
3M
6M
1Y
5Y
Low
$5.87
Day’s Range
High
$6.02
5.87
52 Week Low
$3.05
52-Week Range
52 Week High
$9.01
3.05
1 Day
-
1 Week
-2.87%
1 month return
-7.57%
3 month return
+6.19%
6 month return
+32.32%
1 Year return
+28.03%
3 Years return
-61.45%
5 Years return
-92.8%
10 Years return
-
Institutional Holdings
Suvretta Capital Management, LLC
8.48
Nantahala Capital Management, LLC
7.9
Adage Capital Partners Gp LLC
7.48
Millennium Management LLC
5.29
Vanguard Group Inc
4.62
Vivo Capital, LLC
4.24
Rosalind Advisors, Inc.
4.21

Market Status

Fundamentals
Market Cap
262.13 mln
PB Ratio
5.73
PE Ratio
0
Enterprise Value
175.54 mln
Total Assets
64 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Organisation
Abeona Therapeutics Inc.
Employees
84
Industry
Biotechnology
CEO
Dr. Vishwas  Seshadri M.B.A., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step